SEARCH

SEARCH BY CITATION

References

  • 1
    Aoki-Seki S, O'Brien MC, Ford HJ, Fuji H, Gilbert DA, Cooney DA, Johns DG, et al. In vitro inhibition of hepatitis B virus replication by 2′,3′-dideoxyguanosine, 2′,3′-dideoxyinosine, and 3′-azido-2′,3′-dideoxythymidine in 2.2.15 (PR) cells. J Infect Dis 1991; 164: 843861.
  • 2
    Doong S-L, Tsai C-H, Schinazi RF, Liotta DC, Cheng Y-C. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-di-deoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci USA 1991; 88: 84959499.
  • 3
    Furman PA, Davis M, Liotta DC, Paff M, Frick LW, Nelson DJ, Dornsife RE, et al. The anti-hepatitis B virus activities, cytotox-icities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-l-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob Agents Chemother 1992; 36: 26862692.
  • 4
    Hostetler KL, Richman DD, Sridhar CN, Feigner PL, Feigner J, Ricci J, Gardner ML, et al. Phosphatidyl-dideoxycytidine and phosphatidyl-azidothymidine: assessment of uptake in mouse lymphoid tissues, antiviral activity in HIV-infected cells and in Rauscher leukemia virus-infected mice. Antimicrob Agents Che-mother 1994; 38: 27922797.
  • 5
    Korba BE, Gerin JL. Use of a standardized cell culture assay to assess activities of nucleoside and analogs against hepatitis B virus replication. Antiviral Res 1992; 19: 5570.
  • 6
    Lee B, Luo W, Suzuki S, Robins MJ, Tyrrell DLJ. In vitro and in vivo comparison of the abilities of purine and pyrimidine 2′,3′-dideoxynucleosides to inhibit duck hepadnavirus. Antimicrob Agents Chemother 1989; 33: 336339.
  • 7
    Matthes E, von Janta-Lipinski M, Will H, Schroder HC, Merz H, Steffen R, Muller WE. Inhibition of hepatitis B virus production by modified 2′,3′-dideoxy-thymidine and 2′,3′-dideoxy-5-methylcytidine derivatives. A and in vivo studies. Biochem Pharmacol 1992; 43: 15711577.
  • 8
    Chang C-N, Doong S-L, Zhou JH, Beach JW, Jeong LS, Chi CK, Tsai C-H. Deoxycytidine deaminase-resistant stereoisomer is the active form of (+)-2′,3′-dideoxy-3′-thiacytidine in the inhibition of hepatitis B virus replication. J Biol Chem 1992; 267: 39383942.
  • 9
    Dienstag JL, Perillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. Double-blind, randomized, three-month, dose-ranging trial of lamivudine for chronic hepatitis B. Hepatology 1994; 20: 412A.
  • 10
    Hostetler KY, Korba BE, Sridhar CN, Gardner MF. Antiviral activity of phosphatidyl-dideoxycytidine in hepatitis B infected cells and enhanced hepatic uptake in mice. Antiviral Res 1994; 24: 5967.
  • 11
    Xie H, Voronkov M, Liotta DC, Korba BE, Schinazi RF, Richman DD, Hostetler KY. Phosphatidyl-2′,3′-dideoxy-3′-thiacytidine: synthesis and antiviral activity in hepatitis B and HIV-1 infected cells. Antiviral Res 1995; 28: 113120.
  • 12
    Hornbuckle WE, Graham ES, Roth L, Baldwin BH, Wickenden C, Tennant BC. Laboratory assessment of hepatic injury in the woodchuck (marmota monax). Lab Anim Sci 1985; 35: 376381.
  • 13
    Cote PJ, Ronecker C, Cass K, Schodel F, Peterson D, Tennant B, de Noronha F, et al. New enzyme immunoassays for the serologic detection of woodchuck hepatitis virus infection. Viral Immunology 1993; 6: 161169.
  • 14
    Korba BE, Wells FV, Baldwin B, Cote PJ, Tennant BC, Popper H, Gerin JL. Hepatocullular carcinoma in woodchuck hepatitis virus-infected woodchucks: presence of viral DNA in tumor tissue from chronic carriers and animals serologically recovered from acute infections. Hepatology 1989; 9: 461470.
  • 15
    Hostetler KY, Carson DA, Richman DD. Phosphatidylazidothy-midine. Mechanism of antiretroviral action in CEM cells. J Biol Chem 1991; 266: 1171411717.
  • 16
    Spanjer HH, van Galen M, Roerdink FH, Regts J, Scherphof GL. Intrahepatic distribution of small unilamellar liposomes as a function of liposomal lipid composition. Biochim Biophy Acta 1986; 863: 224230.
  • 17
    Scherphof GL, Spanjer HH, Derksen JTP, Lázár G, Roerdink FH. Targeting of liposomes to liver cells. In: RoerdinkFHD, KroonAM, eds. Drug Carrier Systems. Vol 9. New York; Wiley, “1989”: 281291.
  • 18
    Fiume L, Bonino F, Mattioli A, Chiaberge E, Torrani Cerenzia MR, Busi C, Brunetto MR, et al. Inhibition of hepatitis B virus replication by vidarabine monophosphate conjugated with lactosaminated serum albumin. Lancet 1988; 2: 1315.
  • 19
    Ponzetto P, Fiume L, Forzani B, Song SY, Busi C, Mattioli A, Spinelli C, et al. Adenine arabinoside monophosphate and acyclovir monophosphate coupled to lactosaminated albumin reduce woodchuck hepatitis virus viremia at doses lower than do the unconjugated drugs. Hepatology 1991; 14: 1624.
  • 20
    Enriquez PM, Jung C, Josephson L, Tennant BC. Conjugation of adenine arabinoside 5′-monophosphate to arabinogalactan: synthesis, characterization and antiviral activity. Bioconjugate Chem 1995; 6: 195202.